PolandPoland

Bioton takes on insulin giants

01.03.2012

Polish company Bioton S.A (Warsaw) and Swiss-headquartered generics giant Actavis (Zug) have joined forces to shake up the €12bn world market for recombinant insulins and insulin analogues. At the end of January, Bioton Chairman Ryszard Krauze and Actavis CEO Claudio Albrecht announced that their companies have formed a joint venture for the development and registration of recombinantly produced insulins. While Bioton will develop and produce the insulins, the fourth largest generics producer will sell them in all EU countries, the US, Japan, Switzerland, Norway, Albania, Bosnia & Herzegovina, Croatia, Iceland, Kosovo, Liechtenstein, Montenegro and Macedonia. In Poland, both companies will market the products under their repective brands.

Facing off with the big boys

Under the terms of the agreement, Bioton will receive €22.25m upfront and a further €33.25m in milestones. Both companies expect revenues to reach €1.5bn in the seven years following the market launches of Bioton’s human recombinant insulin, short-acting insulins and long-acting insulins, the first step of which will commence at the end of 2012. The companies will share profits on a 50/50 basis. Actavis also secured an option to market Bioton’s insulins in 24 further markets, paying the Polish bioech firm €1m up front and €0.9m in milestone payments for the privilege.
For Bioton, which is the fourth firm globally to manufacture a human recombinant insulin (“gensulin”), the deal is a unique opportunity for expansion into the global market, which is currently dominated by three big players: Danish Novo Nordisk, French Sanofi and US pharma giant Eli Lilly. “For Bioton, the collaboration with Actavis will fuel faster expansion into high-margin markets,” commented the firm’s CEO Slawomir Ziegert. Albrecht said the deal involved more than just the sale of insulins and insulin analogues. “We are encountering competitor giants when it comes to insulin, and we have to maximise the competitive advantage that we clearly have.”
Bioton wants to be the first company on the market to offer biosimilar versions of recombinantly-produced human insulins, which will be much cheaper than IP-protected originator products. But Pfizer and its Indian manufacturing partner Biocon are hard on the heels of the Polish. Some insulins – such as Lilly’s Humulin, Novo Nordisk’s Novalin or Sanofi’s Lantus – have already lost patent protection. Others, like Levemir (Novo Nordisk) or the fast-acting insulins Humalog (Eli Lilly) and Novalog (Novo Nordisk) will follow in the next two years.
But Actavis also has plans beyond insulin. Albrecht announced the firm intends to launch a biosimilar for bestselling drugs every month during the first eight months of 2012. Bioton can benefit from the generics expert’s plans. Together with the initial announcement of the diabetes pact, which dates back to November 2010, Actavis said it will carry out a due diligence to acquire a 51% stake in Bioton’s Swiss subsidiary Biopartners – a biosimilar specialist.

PolandPoland

06.04.2011

Krakow – Polish drug discovery specialist Selvita S.A. is to carry out virtual compound screening for a protein target provided by the Branford-based Institutes for Pharmaceutical Discovery (IPD) in the US. Selvita said the...

PolandPoland

04.04.2011

Warsaw – Poland’s policy concerning genetically modified organisms (GMOs) has been challenged by the European Commission. In mid-March, the Commission sued Poland at the European Court of Justice (ECJ) for establishing a ban on...

PolandPoland

25.02.2011

Szczecin/Greifswald – In Greifswald, the consensus in mid-March at the “Life Science for Health Economy – Chances and Challenges in Polish-German Cooperation” meeting was that the life sciences would benefit remarkably from...

PolandPoland

06.02.2011

Warsaw – Polish drugmaker Bioton S.A. and Iceland-based generics firm Actavis Group ptc announced in January that they are entering into a marketing and distribution collaboration agreement for Bioton’s insulins and insulin...

PolandPoland

04.11.2010

Warsaw – Merck, Sharp & Dome Polska is to expand its clinical research in the country. The company announced it is investing about US$ 50m in the creation of a data management centre where data from clinical trials conducted in...

PolandPoland

19.09.2010

Warsaw – Polish Agriculture Minister Marek Sawicki has sharply criticised the European Commission’s proposal to let EU member states decide on their own whether or not to plant genetically mod­i­fied crops. “This proposal is not...

PolandPoland

18.09.2010

Krakow – Polish drug developer Selvita sp. z o.o. and Finnish drug and diagnostic firm Orion Corporation (Espoo) have entered into a global collaboration to jointly develop and commercialise Selvita’s oral compound SEL103 as a...

PolandPoland

10.07.2010

Warsaw – While industrial biotechnology companies such as Royal DSM or Novozymes have welcomed new EU climate goals, believing they will provide a kickstart for a bio-based economy, eastern European countries like Bulgaria, the...

PolandPoland

09.07.2010

Kraków/ Espoo – Finland’s Orion Corp and Polish drugmaker Selvita have agreed to collaborate on research and development of Selvita’s oral Alzheimer compound SEL103 program in multiple cognitive disorder indications. According to...

PolandPoland

12.05.2010

Warsaw – Polish biotech firm Bioton SA wants to expand its business to Asia. At the end of April, the producer of recombinant insulin announced that it plans to issue convertible bonds worth EUR26m to fund an expansion of its...

Displaying results 11 to 20 out of 108

< Previous 11-20 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-poland/browse/1/article/bioton-takes-on-insulin-giants.html

Events

All Events

Stock list

All quotes

TOP

  • ADDEX3.13 CHF4.68%
  • CO.DON3.15 EUR4.30%
  • BB BIOTECH146.25 EUR2.17%

FLOP

  • WILEX2.35 EUR-5.24%
  • SANTHERA89.15 CHF-3.10%
  • EVOTEC2.93 EUR-2.33%

TOP

  • SANTHERA89.15 CHF31.2%
  • CO.DON3.15 EUR26.0%
  • PAION3.01 EUR24.4%

FLOP

  • ADDEX3.13 CHF-22.3%
  • EVOTEC2.93 EUR-21.2%
  • MEDIGENE3.95 EUR-15.1%

TOP

  • SANTHERA89.15 CHF2117.7%
  • CO.DON3.15 EUR250.0%
  • PAION3.01 EUR189.4%

FLOP

  • CYTOS0.24 CHF-94.0%
  • MERCK KGAA67.67 EUR-40.6%
  • THERAMETRICS0.09 CHF-40.0%

No liability assumed, Date: 17.09.2014


Current issue

All issues

Product of the week

Products